Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
40.63 USD | -1.67% | -10.57% | +164.79% |
May. 10 | Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating | MT |
May. 09 | Vera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+164.79% | 2.26B | |
+22.82% | 44.96B | |
+1.22% | 42.65B | |
+45.72% | 41.85B | |
-5.31% | 29.04B | |
+11.26% | 26.08B | |
-21.36% | 19.03B | |
+6.56% | 12.75B | |
+28.91% | 12.06B | |
-3.29% | 11.75B |
- Stock Market
- Equities
- VERA Stock
- News Vera Therapeutics, Inc.
- Raymond James Upgrades Vera Therapeutics to Strong Buy From Outperform, Raises PT to $37 From $29